Open Access

Hypoxia-inducible factor (HIF1α) gene expression in human shock states

  • Julien Textoris1, 2Email author,
  • Nathalie Beaufils3,
  • Gabrielle Quintana1,
  • Amin Ben Lassoued3,
  • Laurent Zieleskiewicz1,
  • Sandrine Wiramus1,
  • Valéry Blasco1,
  • Nathalie Lesavre4,
  • Claude Martin1,
  • Jean Gabert3 and
  • Marc Leone1, 2
Critical Care201216:R120

DOI: 10.1186/cc11414

Received: 4 May 2012

Accepted: 10 July 2012

Published: 10 July 2012



Hypoxia-inducible factor-1 (HIF1) controls the expression of genes involved in the cellular response to hypoxia. No information is available on its expression in critically ill patients. Thus, we designed the first clinical study in order to evaluate the role of HIF1α as a prognosis marker in patients suffering from shock.


Fifty consecutive adult patients with shock and 11 healthy volunteers were prospectively enrolled in the study. RNA was extracted from whole blood samples and expression of HIF1α was assessed over the first four hours of shock. The primary objective was to assess HIF1α as a prognostic marker in shock. Secondary objectives were to evaluate the role of HIF1α as a diagnostic and follow-up marker. Patient survival was evaluated at day 28.


The causes of shock were sepsis (78%), hemorrhage (18%), and cardiac dysfunction (4%). HIF1α expression was significantly higher in the shock patients than in the healthy volunteers (121 (range: 72-168) versus 48 (range: 38-54) normalized copies, P <0.01), whatever the measured isoforms. It was similar in non-survivors and survivors (108 (range 84-183) versus 121(range 72-185) normalized copies, P = 0.92), and did not significantly change within the study period.


The present study is the first to demonstrate an increased expression of HIF1α in patients with shock. Further studies are needed to clarify the potential association with outcome. Our findings reinforce the value of monitoring plasma lactate levels to guide the treatment of shock.


Shock states are defined by an acute circulatory failure leading to prolonged and intense tissue hypoxia that may lead to death. Tissue hypoxia is accompanied by a decreased production of ATP in the mitochondria. Hypoxia-inducible factor-1 (HIF1) is a heterodimer made of two sub-units (α and β) [1, 2]. The gene coding for HIF1α is on chromosome 14 (14q21-q24) [3]. HIF1α protein concentration is correlated to cellular oxygen concentration [4]. In hypoxemic conditions, HIF1α is not degraded and accumulates in the cellular nucleus [5]. The effects of HIF1α are stimulation of erythropoiesis, glycolysis, angiogenesis, and vasodilation [1]. In normoxic conditions, HIF1α and its messenger RNA (mRNA) have a very short half-life of five minutes [6, 7]. This suggests that HIF1α is an immediate surrogate marker of cellular oxygenation.

In human shock states, plasma lactate is routinely used as a marker of tissue hypoxia. This marker has been validated for the detection of shock states as well as the prediction of patient outcomes [8, 9]. However, plasma lactate concentrations are influenced by both the production and clearance of lactate. This can be a limitation for the interpretation of plasma lactate concentrations at the bedside. The main objective of the present study was to evaluate the potential prognostic role of HIF1α in ICU patients with shock states. Secondary objectives were to evaluate the role of HIF1α as a detection marker and its correlation with plasma lactate concentrations.

Materials and methods


The study received approval of the Ethics Committee (n° 2009-A00105-52) and was conducted in a 15-bed ICU of a teaching hospital (928 beds). Inclusion criteria were ≥18 years of age and ≤80 years of age, and shock. Shock was defined as follows: hypotension requiring fluid infusion and use of vasopressors, and plasma lactate concentrations >2 mmol/L. The shock should be related to sepsis, bleeding, or cardiac dysfunction. The exclusion criteria were pregnancy and patients without a social security number or deprived of freedom. After a next of kin gave informed consent, the patients with shock were prospectively included.

The patients had to be enrolled within six hours after admission to the ICU. All enrolled patients were equipped with a central line and an arterial catheter. Blood samples for HIF1α (italic refers to mRNA throughout the manuscript) measurements were collected on PaxgeneTM tubes (BD, Franklin Lakes, NJ, USA) and stored at -80°C until RNA extraction. Sampling was performed at the time of shock detection (H0), and after 1 hour (H1), 3 hours (H3), and 4 hours (H4). These time points were selected to follow the early steps of the interventions in patients with shock.

The following variables were collected: age, sex, body mass index, and admission simplified acute physiology score (SAPS) II [10], sequential organ failure assessment (SOFA) score [11], vital signs, type of shock, type of ventilation, drugs needed for the treatment of shock states, biochemical variables, blood cell count and coagulation variables. In addition, arterial blood gas and plasma lactate concentrations were measured at each time point. Mortality was evaluated at day 28. Data on the duration of mechanical ventilation, vasopressor infusion, and ICU stay were also obtained. Treatment goals were based on most available guidelines [8]. Briefly, mean arterial pressure (MAP) was targeted at ≥65 mmHg, urine flow ≥0.5 ml/kg/hour, and central venous oxygen saturation (ScvO2) ≥70%, as described elsewhere [12].

RNA extraction and quantification of HIF1α variants

Total RNA was isolated using the PAXgene™ Blood RNA Kit (Qiagen, Courtaboeuf, France) according to the manufacturer's instructions. A total of 1µg of RNA was reverse transcribed with 200 UI MMLV Reverse Transcriptase following the EAC (Europe Against Cancer) protocol [13]. The cDNA was diluted in a final volume of 50 µl. Amplification and quantification of HIF1α variants were performed as previously described with some modifications of primers and probe sequences (Additional file 1, Figure S1) [14]. Transcripts of the gene coding for TBP (TATA box-binding protein) were also quantified as the endogenous RNA control. Final HIF1α mRNA concentrations were expressed in normalized copy numbers as previously described [14].

The gene HIF1α is composed of 15 exons, resulting in a principal transcript (HIF1αWT) [3, 15] and seven alternative splice variants which have been reported in human cell lines [1620]. Amplification of HIF1αWT showed that it was expressed by circulating blood cells, as well as the splicing variants HIF1αTAG and HIF1α736 (Figure 1). HIF1α516 and HIF1α557 splice variants tested two isoforms coding for negative dominants. These two isoforms were not or were poorly expressed by circulating blood cells. Relative expression of different isoforms was similar between patients and volunteers (Figure 1).
Figure 1

Expression of different HIF1α variants in shock patients (black bars) and controls (grey bars).

In a subgroup of six patients, at H0, blood was collected from both arterial and venous lines. With regard to the expression of HIF1a, no difference was found between the venous and arterial blood samples (data not shown). Then, a group of 11 healthy volunteers, non-smokers, was evaluated for HIF1α expression and used as controls.

Statistical analysis

From previous studies [14, 21], 44 patients with shock were required to achieve a predictive value of 90% with a bias <5% and a 5% risk α. Data were analyzed using the software SPSS and R. Quantitative variables are expressed as median and interquartile range. Qualitative variables are expressed as absolute counts and percentages. Differences between groups were tested using non-parametric tests (Mann-Whitney and Kruskall-Wallis tests). A P level of 0.05 or less was considered significant.


Patient characteristics

Fifty patients with shock (average age 57 (range: 18 to 80 years) and 11 healthy volunteers (average age 50 (range: 29 to 70 years) were prospectively included. Women represented 25% of the cohort of patients and 27% of the cohort of healthy volunteers. The HIF1α expression was unaffected by sex (P = 0.7) or age (P = 0.8). The causes of shock were sepsis, bleeding, and cardiac dysfunction in 39 (78%), 9 (18%), and 2 (4%) cases, respectively (Table 1). Plasma bilirubin concentration and SOFA score differed significantly in survivors and non-survivors (Table 1).
Table 1

Characteristics of the patients according to their survival (day 28).


All patients

number = 50


number = 16


number = 34


Mechanical ventilation (%)

32 (64)

12 (75)

20 (59)


Plasma lactate concentrations (mmol/L)

3.1 (1.9-4.8)

3.8 (2.4-7.2)

3 (1.9-4.3)


MAP (mmHg)

67 (60-72)

70 (52-72(

65 (61-71)


Plasma creatinine (µmol/L)

112 (85-170)

129 (96-184)

99 (80-155)


Plasma bilirubin (mmol/L)

11 (6-21)

18 (12-32)

9 (6-18)


PaO2/FiO2 ratio

186 (112-374)

169 (97-322)

194 (133-376)


PaO2/FiO2 <150

24 (48)

8 (50)

16 (47)



46 (32-61)

55 (36-72)

45 (27-55)


SOFA score

9 (7-11)

10 (9-12)

8 (6-9)


Hemoglobin level H0 (g/dL)

10.0 (8.7-11.4)

10.6 (9.0-11.3)

10 ([8.5-11.5)


MAP, mean arterial pressure; PaO2/FiO2, partial pressure in oxygen related to the inspired fraction of oxygen; SAPS 2, Simplified Acute Physiology Score; SOFA , sequential organ failure assessment.

HIF1α expression

At any time points of the study period, the expression of HIF1α was significantly increased in the patients with shock (Figure 2). At H0, 121 (range: 72 to 168) normalized copies were found in patients with shock, as compared with 46 (range: 38 to 54) normalized copies in healthy volunteers (P <0.01). The detailed values for each time point are presented in Table 2. Of note, the expression of HIF1α did not differ according to the type of shock (data not shown). We did not find a relation between the expression of HIF1α and the absolute number of white blood cells (data not shown).
Figure 2

Expression of HIF1α over time in survivors (white circles) and non survivors (black circles). The horizontal bar indicates the median for each group.

Table 2

Normalized copies of HIF1α in patients with shock according to their survival (day 28) and controls.



number = 50


number = 16


number = 34



109 (78-185)

108 (84-183)

121 (72-185)



132 (69-169)

123 (99-189)

142 (68-167)



123 (72-177)

120 (81-180)

123 (68-157)



109 (73-150)

114 (75-140)

106 (68-150)




number = 10



46 (38-54)*


*P < 0.01 as compared with patients at H0.

HIF1α expression, plasma lactate levels, and outcome

Independently of time points, the HIF1α expression did not differ in the survivors and non-survivors (Table 2). In contrast, with the exception of H0, plasma lactate levels were higher in the non-survivors than in the survivors (Table 3). A weak positive correlation was found between HIF1α expression and plasma lactate concentrations (r2 = 0.1; P = 2.10-5).
Table 3

Plasma lactate (mmol/L) according to the survival of patients at day 28.


All patients

number = 50


number = 16


number = 34



3.1 (1.9-4.8)

3.6 (2.4-7.2)

3.0 (1.9-4.3)



2.8 (1.8-3.6)

3.4 (2.4-7.3)

2.4 (1.8-3.2)



2.5 (1.7-3.2)

3.4 (2.3-6.3)

2.3 (1.7-2.7)



2.5 (1.9-3.4)

3.7 (2.5-5.3)

2.4 (1.6-3.0)


No correlation was found between the HIF1α expression and admission SAPS 2, shock duration, use of mechanical ventilation, SOFA score, and length of ICU stay. The changes in HIF1α expression between H0 and H4 were not predictive of outcome (Figure 2). The HIF1α expression was not correlated with hemoglobin, PaO2, and PaO2/FiO2 ratio.

Expression of HIF1α and response to shock treatment

The expression of HIF1α was significantly higher in 24 patients who received more than two liters of fluid expansion: 124 (range: 100 to 168) normalized copies versus 87 (range: 44 to 141) normalized copies (P = 0.02). No difference was found according to the type of administered fluid (crystalloid versus colloids). The HIF1α expression was not correlated with the dose of vasopressors.


The present study is the first to show an increased expression of HIF1α in patients with shock, as compared with healthy volunteers. The changes in HIF1α expression over time were not correlated with the patient outcome or their treatment responses. Especially, according to our findings, HIF1α expression cannot serve to determine the true level of tissue oxygenation.

A significant increase in HIF1α expression was observed in the patients who received more than two liters of fluid expansion. Nevertheless, no correlation was found with markers of severity, such as MAP, SAPS2 and SOFA score. This finding invites us to hypothesize that this increase was related to a specific effect of fluid infusion. Among several hypotheses, one may consider that large fluid resuscitation can impair tissue oxygenation [22]. Another explanation would be that fluid administration was related to the severity of vasodilation, which in turn may be related to tissue-hypoxia. Further investigations are needed to clarify this issue. Larger groups of patients should be evaluated in order to elucidate such a specific effect.

HIF1α has an ultra-short half-life [23, 24]. One interesting point of the present study is that during the four hours of the study period, the expression of HIF1α was stable. Our initial hypothesis was that due to its ultra-short half-life, HIF1α could provide an immediate reflection of tissue oxygenation. We failed to demonstrate this effect or tissue oxygenation remained unaffected by time and treatment steps. A persistent HIF1α expression has already been demonstrated in cases of lipopolysaccharide stimulation and during a sustained inflammatory response [2528]. Such situations are obviously present in the study patients. A major inflammatory response is present in patients with shock due to the ischemia-reperfusion induced by the treatment of shock [23, 2933]. Because plasma lactate concentrations are not only dependent on production but also on its metabolism, we hypothesized that HIF1α would be a better marker. Our study clearly shows that, at the bedside, lactate remains a better marker of shock than HIF1α. The quantity of protein may be a more accurate marker than the gene expression. Future studies need to clarify this point.

HIF1α is a biomarker of states of cellular hypoxia. Its interest as a marker of outcomes in patients with shock has never been evaluated before. Nevertheless, our results show that, despite attractive speculations about biomarkers, clinical trials are crucial to evaluate their actual role [4, 5]. In the present study, the expression of HIF1α is markedly increased during shock states. The observed increase could be related to the tissue ischemia of shock states or to the inflammatory response. No relation was found between HIF1α expression and oxygenation variables. However, our results show a trend toward an increased expression in patients with low levels of hemoglobin (Hb >8 g/dL: 109 (range: 84 to 174) HIF1α copies versus Hb <8 g/dL: 161 (range: 74 to 270) HIF1α copies; P = 0.4). Larger samples of patients would be required in order to validate this trend. The expression of HIF1α was wider than expected in our rationale. The wide dispersion of the values may be explained by the ultra-short half-life of HIF1α. This may have affected the power of the study.

In our study, HIF1α mRNA expression seems to fail to reflect hypoxia. Several hypotheses may explain this result. First, we measured the expression of HIF1α mRNA in plasma. Actually, in the case of hypoxia, its expression may be more accurate in tissue than in blood. However, regarding our study goals, the collection of tissue biopsy was irrelevant. Second, we may hypothesize that the protein of HIF1α may better reflect tissue hypoxia than its mRNA expression. However, the determination of the protein levels is time consuming, whereas that of RNA levels can be performed in a short time. Our study was aimed at providing an early marker in real-life clinical practice. Finally, divergently from HIF1α, plasma lactate levels may reflect pyruvate accumulation rather than cell hypoxia in sepsis and injury [9]. The evaluation of HIF1α values beyond four hours may also bring new evidence of its role in patients with shock. Future studies are needed to determine whether its expression during late phases of shock may be related to early interventions. Finally, it is important to consider that the present study focused on blood determinations. This could not reflect with enough accuracy the state of ischemia at the tissue level [21].


The present study is the first to show the increased expression of HIF1α, a transcription factor that controls genes implied in the response to cellular ischemia, in patients with shock. Within the limitations of the study, HIF1α expression was not correlated with the outcome of patients. Further studies including larger groups of patients are warranted to clarify this issue.

Key messages

  • Hypoxia-inducible factor 1 alpha (HIF1α) is a transcription factor that controls the expression of genes in response to cellular hypoxia

  • HIF1α mRNA is elevated in patients with shock, as compared to healthy volunteers

  • HIF1α expression was not correlated to patient outcome

  • HIF1α expression over the first hours of shock management was independent of clinical evolution and outcome

  • To assess patients with shock, plasma lactate levels seem better than HIF1α expression



Hypoxia Inducible Factor 1 alpha


Simplified Acute Physiological Score


Sequential Organ Failure Assessment.



This work was supported by the Grant 'Appel d'Offre de Recherche Clinique-Assistance Publique des Hôpitaux de Marseille' n°2009-A00364-53, Marseille, France.

Authors’ Affiliations

Service d'anesthésie et de réanimation, Hôpital Nord, Assistance Publique-Hôpitaux de Marseille, Chemin des bourrely
URMITE, CNRS U7278, INSERM U1095, Faculté de médecine Timone, Aix-Marseille Univ, Boulevard Jean Moulin
Laboratoire de Biochimie et Biologie Moléculaire, Hôpital Nord, Assistance Publique-Hôpitaux de Marseille, Chemin des bourrely
Centre d'Investigation Clinique, Hôpital Nord, Assistance Publique-Hôpitaux de Marseille, Chemin des bourrely


  1. Semenza GL, Agani F, Iyer N, Jiang BH, Leung S, Wiener C, Yu A: Hypoxia-inducible factor 1: from molecular biology to cardiopulmonary physiology. Chest. 1998, 114: 40S-45S. 10.1378/chest.114.1_Supplement.40S.PubMedView ArticleGoogle Scholar
  2. Hellwig-Bürgel T, Rutkowski K, Metzen E, Fandrey J, Jelkmann W: Interleukin-1beta and tumor necrosis factor-alpha stimulate DNA binding of hypoxia-inducible factor-1. Blood. 1999, 94: 1561-1567.PubMedGoogle Scholar
  3. Semenza GL, Rue EA, Iyer NV, Pang MG, Kearns WG: Assignment of the hypoxia-inducible factor 1alpha gene to a region of conserved synteny on mouse chromosome 12 and human chromosome 14q. Genomics. 1996, 34: 437-439. 10.1006/geno.1996.0311.PubMedView ArticleGoogle Scholar
  4. Schumacker PT: Hypoxia-inducible factor-1 (HIF-1). Crit Care Med. 2005, 33: S423-425. 10.1097/01.CCM.0000191716.38566.E0.PubMedView ArticleGoogle Scholar
  5. Maxwell PH: Hypoxia-inducible factor as a physiological regulator. Exp Physiol. 2005, 90: 791-797. 10.1113/expphysiol.2005.030924.PubMedView ArticleGoogle Scholar
  6. Berra E, Richard DE, Gothié E, Pouysségur J: HIF-1-dependent transcriptional activity is required for oxygen-mediated HIF-1alpha degradation. FEBS Lett. 2001, 491: 85-90. 10.1016/S0014-5793(01)02159-7.PubMedView ArticleGoogle Scholar
  7. Wang GL, Jiang BH, Rue EA, Semenza GL: Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA. 1995, 92: 5510-5514. 10.1073/pnas.92.12.5510.PubMedPubMed CentralView ArticleGoogle Scholar
  8. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut J-F, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent J-L: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med. 2008, 34: 17-60. 10.1007/s00134-007-0934-2.PubMedPubMed CentralView ArticleGoogle Scholar
  9. Levy B: Lactate and shock state: the metabolic view. Curr Opin Crit Care. 2006, 12: 315-321. 10.1097/01.ccx.0000235208.77450.15.PubMedView ArticleGoogle Scholar
  10. Le Gall JR, Lemeshow S, Saulnier F: A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA. 1993, 270: 2957-2963. 10.1001/jama.1993.03510240069035.PubMedView ArticleGoogle Scholar
  11. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, Reinhart CK, Suter PM, Thijs LG: The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996, 22: 707-710. 10.1007/BF01709751.PubMedView ArticleGoogle Scholar
  12. Leone M, Blidi S, Antonini F, Meyssignac B, Bordon S, Garcin F, Charvet A, Blasco V, Albanèse J, Martin C: Oxygen tissue saturation is lower in nonsurvivors than in survivors after early resuscitation of septic shock. Anesthesiology. 2009, 111: 366-371. 10.1097/ALN.0b013e3181aae72d.PubMedView ArticleGoogle Scholar
  13. Gabert J, Beillard E, van der Velden VHJ, Bi W, Grimwade D, Pallisgaard N, Barbany G, Cazzaniga G, Cayuela JM, Cavé H, Pane F, Aerts JLE, De Micheli D, Thirion X, Pradel V, González M, Viehmann S, Malec M, Saglio G, van Dongen JJM: Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia. 2003, 17: 2318-2357. 10.1038/sj.leu.2403135.PubMedView ArticleGoogle Scholar
  14. Dales J-P, Beaufils N, Silvy M, Picard C, Pauly V, Pradel V, Formisano-Tréziny C, Bonnier P, Giusiano S, Charpin C, Gabert J: Hypoxia inducible factor 1alpha gene (HIF-1alpha) splice variants: potential prognostic biomarkers in breast cancer. BMC Med. 2010, 8: 44-10.1186/1741-7015-8-44.PubMedPubMed CentralView ArticleGoogle Scholar
  15. Iyer NV, Leung SW, Semenza GL: The human hypoxia-inducible factor 1alpha gene: HIF1A structure and evolutionary conservation. Genomics. 1998, 52: 159-165. 10.1006/geno.1998.5416.PubMedView ArticleGoogle Scholar
  16. Gothié E, Richard DE, Berra E, Pagès G, Pouysségur J: Identification of alternative spliced variants of human hypoxia-inducible factor-1alpha. J Biol Chem. 2000, 275: 6922-6927. 10.1074/jbc.275.10.6922.PubMedView ArticleGoogle Scholar
  17. Chun YS, Choi E, Yeo EJ, Lee JH, Kim MS, Park JW: A new HIF-1 alpha variant induced by zinc ion suppresses HIF-1-mediated hypoxic responses. J Cell Sci. 2001, 114: 4051-4061.PubMedGoogle Scholar
  18. Chun Y-S, Choi E, Kim T-Y, Kim M-S, Park J-W: A dominant-negative isoform lacking exons 11 and 12 of the human hypoxia-inducible factor-1alpha gene. Biochem J. 2002, 362: 71-79. 10.1042/0264-6021:3620071.PubMedPubMed CentralView ArticleGoogle Scholar
  19. Lee K-H, Park J-W, Chun Y-S: Non-hypoxic transcriptional activation of the aryl hydrocarbon receptor nuclear translocator in concert with a novel hypoxia-inducible factor-1alpha isoform. Nucleic Acids Res. 2004, 32: 5499-5511. 10.1093/nar/gkh880.PubMedPubMed CentralView ArticleGoogle Scholar
  20. Depping R, Hägele S, Wagner KF, Wiesner RJ, Camenisch G, Wenger RH, Katschinski DM: A dominant-negative isoform of hypoxia-inducible factor-1 alpha specifically expressed in human testis. Biol Reprod. 2004, 71: 331-339. 10.1095/biolreprod.104.027797.PubMedView ArticleGoogle Scholar
  21. Leone M, Boutière B, Camoin-Jau L, Albanèse J, Horschowsky N, Mège J-L, Martin C, Dignat-George F: Systemic endothelial activation is greater in septic than in traumatic-hemorrhagic shock but does not correlate with endothelial activation in skin biopsies. Crit Care Med. 2002, 30: 808-814. 10.1097/00003246-200204000-00015.PubMedView ArticleGoogle Scholar
  22. Legrand M, Mik EG, Balestra GM, Lutter R, Pirracchio R, Payen D, Ince C: Fluid resuscitation does not improve renal oxygenation during hemorrhagic shock in rats. Anesthesiology. 2010, 112: 119-127. 10.1097/ALN.0b013e3181c4a5e2.PubMedView ArticleGoogle Scholar
  23. Hellwig-Bürgel T, Stiehl DP, Wagner AE, Metzen E, Jelkmann W: Review: hypoxia-inducible factor-1 (HIF-1): a novel transcription factor in immune reactions. J Interferon Cytokine Res. 2005, 25: 297-310. 10.1089/jir.2005.25.297.PubMedView ArticleGoogle Scholar
  24. Görlach A, Diebold I, Schini-Kerth VB, Berchner-Pfannschmidt U, Roth U, Brandes RP, Kietzmann T, Busse R: Thrombin activates the hypoxia-inducible factor-1 signaling pathway in vascular smooth muscle cells: role of the p22(phox)-containing NADPH oxidase. Circ Res. 2001, 89: 47-54. 10.1161/hh1301.092678.PubMedView ArticleGoogle Scholar
  25. Koury J, Deitch EA, Homma H, Abungu B, Gangurde P, Condon MR, Lu Q, Xu D-Z, Feinman R: Persistent HIF-1alpha activation in gut ischemia/reperfusion injury: potential role of bacteria and lipopolysaccharide. Shock. 2004, 22: 270-277. 10.1097/01.shk.0000135256.67441.3f.PubMedView ArticleGoogle Scholar
  26. Frede S, Stockmann C, Freitag P, Fandrey J: Bacterial lipopolysaccharide induces HIF-1 activation in human monocytes via p44/42 MAPK and NF-kappaB. Biochem J. 2006, 396: 517-527. 10.1042/BJ20051839.PubMedPubMed CentralView ArticleGoogle Scholar
  27. Blouin CC, Pagé EL, Soucy GM, Richard DE: Hypoxic gene activation by lipopolysaccharide in macrophages: implication of hypoxia-inducible factor 1alpha. Blood. 2004, 103: 1124-1130.PubMedView ArticleGoogle Scholar
  28. Peyssonnaux C, Cejudo-Martin P, Doedens A, Zinkernagel AS, Johnson RS, Nizet V: Cutting edge: essential role of hypoxia inducible factor-1alpha in development of lipopolysaccharide-induced sepsis. J Immunol. 2007, 178: 7516-7519.PubMedView ArticleGoogle Scholar
  29. Shih SC, Claffey KP: Role of AP-1 and HIF-1 transcription factors in TGF-beta activation of VEGF expression. Growth Factors. 2001, 19: 19-34. 10.3109/08977190109001073.PubMedView ArticleGoogle Scholar
  30. Richard DE, Berra E, Pouyssegur J: Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1alpha in vascular smooth muscle cells. J Biol Chem. 2000, 275: 26765-26771.PubMedGoogle Scholar
  31. Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, Semenza GL: Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res. 1999, 59: 3915-3918.PubMedGoogle Scholar
  32. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL: HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol. 2001, 21: 3995-4004. 10.1128/MCB.21.12.3995-4004.2001.PubMedPubMed CentralView ArticleGoogle Scholar
  33. Nizet V, Johnson RS: Interdependence of hypoxic and innate immune responses. Nat Rev Immunol. 2009, 9: 609-617. 10.1038/nri2607.PubMedPubMed CentralView ArticleGoogle Scholar


© Textoris et al.; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.